Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12621001524886
Ethics application status
Approved
Date submitted
4/11/2021
Date registered
9/11/2021
Date last updated
8/12/2024
Date data sharing statement initially provided
9/11/2021
Type of registration
Prospectively registered

Titles & IDs
Public title
Queensland COVID-19 Vaccination (QoVAX) Safety and Efficacy Trial Program: Mixed Dose 1 and 2 Study
Scientific title
Queensland COVID-19 Vaccination (QoVAX) Safety and Efficacy Trial Program: Mixed Dose 1 and 2 Study
Secondary ID [1] 305682 0
Nil known
Universal Trial Number (UTN)
U1111-1271-3028
Trial acronym
Nil
Linked study record
Not applicable

Health condition
Health condition(s) or problem(s) studied:
COVID-19 324156 0
SARS-CoV-2 324157 0
Condition category
Condition code
Infection 321630 321630 0 0
Other infectious diseases
Inflammatory and Immune System 321631 321631 0 0
Normal development and function of the immune system
Respiratory 321719 321719 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Observational
Patient registry
False
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Heterologous COVID-19 vaccines (BNT162b2 (BioNTech, Pfizer)/ChAdOx1 (Oxford, AstraZeneca) or ChAdOx1/BNT162b2) for doses 1 and 2

Participants complete a questionnaire and have blood and saliva samples collected at 4 - 6 months post the second vaccine dose. The questionnaire and samples are repeated at 4 weeks after the COVID-19 booster dose, and 12-months post the date of recruitment.
Intervention code [1] 322075 0
Not applicable
Comparator / control treatment
Homologous COVID-19 vaccines BNT162b2/BNT162b2 (BioNTech, Pfizer) or ChAdOx1/ChAdOx1 (Oxford, AstraZeneca) for doses 1 and 2

Participants complete a questionnaire and have blood and saliva samples collected at 4 - 6 months post the second vaccine dose. The questionnaire and samples are repeated at 4 weeks after the COVID-19 booster dose, and at 12-months post the date of recruitment.
Control group
Active

Outcomes
Primary outcome [1] 329394 0
Serum IgG antibodies titres to the SARS-CoV2 spike protein measured using Abbott Core Laboratories' chemiluminescent microparticle immunoassay (CMIA)
Timepoint [1] 329394 0
4 - 6 months from the second dose of vaccine and repeated at 4 weeks after the COVID-19 booster dose, and at 12 months following the date of recruitment.
Secondary outcome [1] 402446 0
Serum IgG antibody titres to SARS-CoV-2 nucleocapsid protein measured by using Abbott Laboratories' chemiluminescent microparticle immunoassay (CMIA)
Timepoint [1] 402446 0
4 - 6 months from the second dose of vaccine and repeated at 4 weeks after the COVID-19 booster dose, and at 12 months following the date of recruitment.
Secondary outcome [2] 402448 0
Serum IgA antibody titres to the SARS-CoV-2 spike protein measured using the Euroimmune SARS-CoV-2 domain IgA enzyme-linked immunosorbent assay (ELISA)
Timepoint [2] 402448 0
4 - 6 months from the second dose of vaccine and repeated at 4 weeks after the COVID-19 booster dose, and at 12 months following the date of recruitment. This additional collection was added after 179 participants had consented to participate in this study.
Secondary outcome [3] 402449 0
Immunocompetence assessed via full blood counts with differential analysis of (CD20, CD4, CD8, CD28, CD56, CD27, with additional CD8 immunosenescence markers; CD28 and CD57, and senescent B cells; CD19 pos CD27 neg IgD negative. All components will be assessed as a composite outcome.
Timepoint [3] 402449 0
4 - 6 months from the second dose of vaccine and repeated at 4 weeks after the COVID-19 booster dose, and at 12 months following the date of recruitment.
Secondary outcome [4] 402659 0
Titre of neutralizing antibody to the SARS-CoV2 spike protein for variants of concern (UK, RSA. Delta and QLD02), These will be assessed as a composite secondary outcome
Timepoint [4] 402659 0
4 - 6 months from the second dose of vaccine and repeated at 4 weeks after the COVID-19 booster dose, and at 12 months following the date of recruitment.
Secondary outcome [5] 402660 0
Concentration of cytokines in peripheral blood mononuclear cells (IL-1 alpha, IFN-gamma 2, IFN gamma, TNF, MCP-1 CCL2, IL-6, IL-8 CXCL8, IL-10, IL-12p70, IL-17A, IL-18, IL-23 and IL-33) using Biolegend LegendPlex Inflammation Panel Kit. These will be assessed as a composite secondary outcome.
Timepoint [5] 402660 0
4 - 6 months from the second dose of vaccine and repeated at 4 weeks after the COVID-19 booster dose, and at 12 months following the date of recruitment.
Secondary outcome [6] 402661 0
Genetic array sequences affecting immunity to heterologous and homologous doses of COVID-19 vaccines (human leukocyte antigen loci, other immune response genes). These will be assessed as a composite secondary outcome.
Timepoint [6] 402661 0
4 - 6 months from the second dose of vaccine and repeated at 4 weeks after the COVID-19 booster dose, and at 12 months following the date of recruitment.
Secondary outcome [7] 402662 0
Cellular immune responses including IFN-gamma, IL-2 and TNF production. Activation-induced marker (OX40+CD137+) CD4+ T and (CD69+CD137+) CD8+ T cells, memory T cell responses defined using CD45RO, CCR7 and CD62L, and Granzyme-B and Perforin expression by activated CD8 T cells, and CD20+ and CD27+ memory B cells. These will be assessed as a composite secondary outcome
Timepoint [7] 402662 0
4 - 6 months from the second dose of vaccine and repeated at 4 weeks after the COVID-19 booster dose, and at 12 months following the date of recruitment.
Secondary outcome [8] 402664 0
Participant reported local and systemic reactions following each dose of vaccine. These will be assessed as a composite secondary outcome.
Timepoint [8] 402664 0
Data collected 4 - 6 months from the second dose of vaccine and repeated at 4 weeks after the COVID-19 booster dose.
Secondary outcome [9] 402750 0
Saliva IgA antibody titres to the SARS-CoV-2 spike protein measured using the Euroimmune SARS-CoV-2 domain IgA enzyme-linked immunosorbent assay (ELISA)
Timepoint [9] 402750 0
4 - 6 months from the second dose of vaccine and repeated at 4 weeks after the COVID-19 booster dose.

Eligibility
Key inclusion criteria
People in Queensland 18 years of age and older, who have received two doses of BNT162b2 or ChAdOx1 COVID vaccines, the second of which was received between 120-180 days prior to giving consent,
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. Unable or decline to give informed consent
2. Have a contraindication to venepuncture
3. Insufficient literacy to read and understand the English or translated version of the participant information and consent forms who do not have a family member or interpreter to assist
4. Do not posses a smart phone or computer to access the participant information and complete the consent form and fill the questionnaire.
5. Are unable or unwilling to reach a pathology collection centre to donate samples.

Study design
Purpose
Screening
Duration
Longitudinal
Selection
Defined population
Timing
Both
Statistical methods / analysis
The primary outcome measure is serum IgG spike concentration at 4-6 month post vaccine Dose 2, and 4 weeks after the COVID-19 booster dose. The comparison of interest is heterologous compared to homologous vaccine groups. Data will be analysed using a General Linear Model with log-normal distribution to compare (log) fold-increase in serum IgG. Treatment group, vaccine type given at Dose 1 and 2, and age will be used as covariates to adjust for potential confounding given ATAGI has recommended the AZ vaccine for older and Pfizer for younger individuals. Values below the limit of detection (LoD) of the test will be replaced by values equal to the LoD divided by two. No replacement of missing data will be considered for the primary outcome. Univariate analysis will be used to explore the relationships between IgG and host intrinsic and extrinsic factors, pre-existing health conditions, medications and vulnerable groups. Additional exploratory descriptive analysis including IgG to SARS-CoV-2 nucleocapsid, HLA-type, gender, immunocompetence and ethnicity as covariates are planned. Secondary outcomes include for a subset of patients: neutralizing antibody titres, serum and salivary IgA levels, and cell mediated immunity to original vaccine strain. Descriptive comparative analysis between Groups 1 and 2 and other targeted subgroups for the primary outcomes will also be undertaken.
Medium-term health analysis of participants will be evaluated by integration of result test results with vaccine notification data to investigate vaccine efficacy outcomes in relation to immune response and data on other health and social determinants.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
6/12/2021
Actual
7/01/2022
Date of last participant enrolment
Anticipated
1/04/2022
Actual
3/05/2022
Date of last data collection
Anticipated
30/06/2023
Actual
30/06/2023
Sample size
Target
2000
Accrual to date
Final
586
Recruitment in Australia
Recruitment state(s)
QLD

Funding & Sponsors
Funding source category [1] 310044 0
Government body
Name [1] 310044 0
Queensland Health
Country [1] 310044 0
Australia
Primary sponsor type
Government body
Name
Metro North Hospital and Health Service
Address
Physical address
33 Charlotte Street
Brisbane Queensland 4001

Postal address
GPO Box 48 Brisbane, Queensland 4001
Country
Australia
Secondary sponsor category [1] 311097 0
None
Name [1] 311097 0
Address [1] 311097 0
Country [1] 311097 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 309740 0
Metro North Health HREC (EC00172)
Ethics committee address [1] 309740 0
Ethics committee country [1] 309740 0
Australia
Date submitted for ethics approval [1] 309740 0
28/09/2021
Approval date [1] 309740 0
02/11/2021
Ethics approval number [1] 309740 0
HREC/2021/QRBW/79314

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 115226 0
A/Prof Michael Nissen
Address 115226 0
Office of Research, Metro North Health
Level 7, Block 7, RBWH campus, Herston QLD 4029
Country 115226 0
Australia
Phone 115226 0
+61 736479637
Fax 115226 0
Email 115226 0
MetroNorthHealth-ClinicalTrials@health.qld.gov.au
Contact person for public queries
Name 115227 0
Dr Tania Crough
Address 115227 0
Office of Research, Metro North Health
Level 7, Block 7, RBWH campus, Herston QLD 4029
Country 115227 0
Australia
Phone 115227 0
+61 736479637
Fax 115227 0
Email 115227 0
MetroNorthResearch-ClinicalTrials@health.qld.gov.au
Contact person for scientific queries
Name 115228 0
Dr Tania Crough
Address 115228 0
Office of Research, Metro North Health
Level 7, Block 7, RBWH campus, Herston QLD 4029
Country 115228 0
Australia
Phone 115228 0
+61 736479637
Fax 115228 0
Email 115228 0
MetroNorthHealth-ClinicalTrials@health.qld.gov.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
13955Informed consent formBy request to MetroNorthResearch-ClinicalTrials@health.qld.gov.au



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.